Johnson & Johnson Shareholders’ Equity Growth & History (JNJ)
Johnson & Johnson's shareholders’ equity was $81.54B for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | $81.54B | $10.05B | +14.06% |
| 2024 | 2024-12-29 | $71.49B | $2.72B | +3.95% |
| 2023 | 2023-12-31 | $68.77B | −$8.03B | −10.46% |
| 2022 | 2023-01-01 | $76.80B | $2.78B | +3.76% |
| 2021 | 2022-01-02 | $74.02B | $10.74B | +16.98% |
| 2020 | 2021-01-04 | $63.28B | $3.81B | +6.40% |
| 2019 | 2019-12-29 | $59.47B | −$281.0M | −0.47% |
| 2018 | 2018-12-30 | $59.75B | −$408.0M | −0.68% |
| 2017 | 2017-12-31 | $60.16B | −$10.26B | −14.57% |
| 2016 | 2017-01-01 | $70.42B | −$732.0M | −1.03% |
| 2015 | 2016-01-03 | $71.15B | $1.40B | +2.00% |
| 2014 | 2014-12-28 | $69.75B | −$4.30B | −5.81% |
| 2013 | 2013-12-29 | $74.05B | $9.23B | +14.23% |
| 2012 | 2012-12-30 | $64.83B | $7.75B | +13.57% |
| 2011 | 2012-01-01 | $57.08B | $501.0M | +0.89% |
| 2010 | 2011-01-02 | $56.58B | $5.99B | +11.84% |
| 2009 | 2010-01-03 | $50.59B | $8.08B | +19.00% |
| 2008 | 2008-12-28 | $42.51B | −$808.0M | −1.87% |
| 2007 | 2007-12-30 | $43.32B | — | — |
Johnson & Johnson quarterly shareholders’ equity
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $84.97B | $6.50B | +8.28% |
| Q1 2026 | 2026-03-29 | $81.19B | $3.08B | +3.94% |
| Q4 2025 | 2025-12-28 | $81.54B | $10.05B | +14.06% |
| Q3 2025 | 2025-09-28 | $79.28B | $9.12B | +13.00% |
| Q2 2025 | 2025-06-29 | $78.47B | $6.93B | +9.69% |
| Q1 2025 | 2025-03-30 | $78.11B | $8.09B | +11.55% |
| Q4 2024 | 2024-12-29 | $71.49B | $2.72B | +3.95% |
| Q3 2024 | 2024-09-29 | $70.16B | −$1.07B | −1.50% |
| Q2 2024 | 2024-06-30 | $71.54B | −$3.61B | −4.81% |
| Q1 2024 | 2024-03-31 | $70.02B | −$849.0M | −1.20% |
| Q4 2023 | 2023-12-31 | $68.77B | −$8.03B | −10.46% |
| Q3 2023 | 2023-10-01 | $71.23B | −$3.37B | −4.52% |
| Q2 2023 | 2023-07-02 | $75.15B | −$1.21B | −1.58% |
| Q1 2023 | 2023-04-02 | $70.87B | −$3.84B | −5.14% |
| Q4 2022 | 2023-01-01 | $76.80B | $2.78B | +3.76% |
| Q3 2022 | 2022-10-02 | $74.60B | $4.33B | +6.16% |
| Q2 2022 | 2022-07-03 | $76.36B | $6.78B | +9.74% |
| Q1 2022 | 2022-04-03 | $74.71B | $8.88B | +13.48% |
| Q4 2021 | 2022-01-02 | $74.02B | — | — |
| Q3 2021 | 2021-10-03 | $70.27B | $5.80B | +8.99% |
| Q2 2021 | 2021-07-04 | $69.58B | $6.60B | +10.48% |
| Q1 2021 | 2021-04-04 | $65.83B | $4.54B | +7.41% |
| Q4 2020 | 2021-01-04 | $63.28B | $3.81B | +6.40% |
| As of Jan 3, 2021 | 2021-01-03 | $63.28B | $3.81B | +6.40% |
| Q3 2020 | 2020-09-27 | $64.47B | $6.26B | +10.76% |
| Q2 2020 | 2020-06-28 | $62.98B | $2.19B | +3.61% |
| Q1 2020 | 2020-03-29 | $61.29B | $2.34B | +3.97% |
| Q4 2019 | 2019-12-29 | $59.47B | −$281.0M | −0.47% |
| Q3 2019 | 2019-09-29 | $58.21B | −$6.42B | −9.93% |
| Q2 2019 | 2019-06-30 | $60.78B | −$2.10B | −3.35% |
| Q1 2019 | 2019-03-31 | $58.95B | −$4.30B | −6.80% |
| Q4 2018 | 2018-12-30 | $59.75B | −$408.0M | −0.68% |
| Q3 2018 | 2018-09-30 | $64.63B | −$9.35B | −12.64% |
| Q2 2018 | 2018-07-01 | $62.89B | −$9.03B | −12.56% |
| Q1 2018 | 2018-04-01 | $63.26B | −$7.09B | −10.07% |
| Q4 2017 | 2017-12-31 | $60.16B | −$10.26B | −14.57% |
| Q3 2017 | 2017-10-01 | $73.98B | $1.21B | +1.66% |
| Q2 2017 | 2017-07-02 | $71.92B | −$551.0M | −0.76% |
| Q1 2017 | 2017-04-02 | $70.34B | −$2.31B | −3.17% |
| Q4 2016 | 2017-01-01 | $70.42B | −$732.0M | −1.03% |
| Q3 2016 | 2016-10-02 | $72.77B | $1.22B | +1.70% |
| Q2 2016 | 2016-07-03 | $72.47B | $1.34B | +1.89% |
| Q1 2016 | 2016-04-03 | $72.65B | $4.77B | +7.03% |
| Q4 2015 | 2016-01-03 | $71.15B | $1.40B | +2.00% |
| Q3 2015 | 2015-09-27 | $71.55B | −$5.04B | −6.58% |
| Q2 2015 | 2015-06-28 | $71.13B | −$6.92B | −8.86% |
| Q1 2015 | 2015-03-29 | $67.88B | −$8.70B | −11.37% |
| Q4 2014 | 2014-12-28 | $69.75B | −$4.30B | −5.81% |
| Q3 2014 | 2014-09-28 | $76.59B | $6.79B | +9.72% |
| Q2 2014 | 2014-06-29 | $78.05B | $8.38B | +12.03% |
| Q1 2014 | 2014-03-30 | $76.58B | $9.73B | +14.55% |
| Q4 2013 | 2013-12-29 | $74.05B | $9.23B | +14.23% |
| Q3 2013 | 2013-09-29 | $69.80B | $6.04B | +9.48% |
| Q2 2013 | 2013-06-30 | $69.67B | $9.23B | +15.27% |
| Q1 2013 | 2013-03-31 | $66.86B | $5.49B | +8.94% |
| Q4 2012 | 2012-12-30 | $64.83B | $7.75B | +13.57% |
| Q3 2012 | 2012-09-30 | $63.76B | $2.23B | +3.63% |
| Q2 2012 | 2012-07-01 | $60.43B | −$1.70B | −2.73% |
| Q1 2012 | 2012-04-01 | $61.37B | $1.50B | +2.51% |
| Q4 2011 | 2012-01-01 | $57.08B | $501.0M | +0.89% |
| Q3 2011 | 2011-10-02 | $61.53B | $4.24B | +7.39% |
| Q2 2011 | 2011-07-03 | $62.13B | $9.28B | +17.56% |
| Q1 2011 | 2011-04-03 | $59.86B | $6.95B | +13.13% |
| Q4 2010 | 2011-01-02 | $56.58B | $5.99B | +11.84% |
| Q3 2010 | 2010-10-03 | $57.29B | $6.91B | +13.71% |
| Q2 2010 | 2010-07-04 | $52.85B | $6.60B | +14.28% |
| Q1 2010 | 2010-04-04 | $52.91B | — | — |
| Q4 2009 | 2010-01-03 | $50.59B | $8.08B | +19.00% |
| Q3 2009 | 2009-09-27 | $50.38B | — | — |
| Q2 2009 | 2009-06-28 | $46.25B | — | — |
| Q4 2008 | 2008-12-28 | $42.51B | — | — |
Johnson & Johnson shareholders’ equity trends
Over the last five fiscal years, Johnson & Johnson's shareholders’ equity increased from $63.28B to $81.54B, a change of $18.27B. The latest reported quarter, Q2 2026, shows $84.97B.
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...